Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$42.47 USD
+0.40 (0.95%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $42.44 -0.03 (-0.07%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/1/24 |
---|---|
Current Quarter | -0.61 |
EPS Last Quarter | NA |
Last EPS Surprise | NA |
ABR | 2.64 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -2.72 |
Next Year | -2.93 |
EPS (TTM) | -2.50 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | 13.52M |
# of Estimates | NA | NA | NA | 1 |
High Estimate | NA | NA | NA | 13.52M |
Low Estimate | NA | NA | NA | 13.52M |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.61 | -0.62 | -2.72 | -2.93 |
# of Estimates | 5 | 5 | 10 | 8 |
Most Recent Consensus | -0.60 | -0.57 | -2.97 | -3.18 |
High Estimate | -0.55 | -0.57 | -2.37 | -2.54 |
Low Estimate | -0.70 | -0.71 | -3.19 | -3.20 |
Year ago EPS | -0.67 | -0.63 | NA | -2.72 |
Year over Year Growth Est. | 8.96% | 1.59% | NA | -7.77% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 1 | 1 | 2 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.61 | -0.62 | -2.72 | -2.93 |
7 Days Ago | -0.61 | -0.62 | -2.72 | -2.93 |
30 Days Ago | -0.61 | -0.62 | -2.72 | -2.93 |
60 Days Ago | -0.59 | -0.60 | -2.63 | -2.86 |
90 Days Ago | -0.59 | -0.60 | -2.63 | -2.86 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.61 | -0.62 | -2.72 | -2.93 |
Zacks Consensus Estimate | -0.61 | -0.62 | -2.72 | -2.93 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | NA | -0.61 | -0.63 | -0.67 | NA |
Estimate | NA | -0.63 | -0.65 | -0.67 | NA |
Difference | NA | 0.02 | 0.02 | 0.00 | 0.01 |
Surprise | NA | 3.17% | 3.08% | 0.00% | 2.08% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more